MOR 208

Drug Profile

MOR 208

Alternative Names: anti-CD19 MAb XmAb5574; anti-CD19 MoAb XmAb5574; MOR-00208; MOR-208; XENP-5574; XmAb-5574

Latest Information Update: 13 Feb 2017

Price : $50

At a glance

  • Originator Xencor
  • Developer MorphoSys; The Ohio State University Comprehensive Cancer Center; Xencor
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD19 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Diffuse large B cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Diffuse large B cell lymphoma
  • Phase II Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 14 Dec 2016 9208751- Updated kdm with dosing info in COSMOS trial
  • 03 Dec 2016 Efficacy and adverse event data from a phase II trial in Non-Hodgkin's lymphoma presented at 58th Annual Meeting and Exposition of the American Society of Hematology
  • 03 Dec 2016 Efficacy and adverse events data from a phase II trial in Chronic lymphocytic leukaemia, Small lymphocytic lymphoma and Prolymphocytic leukaemia (relapsed, refractory or previously untreated) presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top